Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer
JAMA Oncology May 07, 2019
Berner F, et al. - Researchers performed this cohort study of 73 patients with non–small cell lung cancer who received anti–PD-1 (programmed cell death 1) therapy, for the underlying pathophysiologic processes of autoimmune skin toxic effects induced by anti–PD-1 therapy. Non–small cell lung cancers and the skin mediated autoimmune skin toxic effects were noted to share nine T-cell antigens. Mediatory role of these T cells in the tumor regression is suggested in patients who responded to therapy. Findings suggest the predictive value of autoimmune toxic effects associated with checkpoint blockade for clinical responses; these may provide opportunities to identify cancer T-cell targets.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries